Clorox has clawed gross margin back from a 36% wartime trough to ~45% and rebuilt EPS from $1.21 to $6.56 — but revenue has sat at ~$7.1B for five straight years, and a sudden CEO exit just reintroduced the one risk a slow-growth compounder can't easily absorb. At a ~5% yield and ~15x earnings, the income is the thesis; the growth is the question.
Clorox (CLX) is a low-beta consumer-staples franchise — bleach, Pine-Sol, Glad, Kingsford, Brita, Burt's Bees, Hidden Valley — that spent 2022-2024 absorbing a margin collapse, a major cyberattack, and a portfolio overhaul, then engineered one of the cleaner gross-margin recoveries in staples: from ~36% back to ~45%. The catch is that none of it grew the top line, which has hovered at ~$7.1B since FY2020. With the stock down from $132 to ~$97 over the past year and CEO Linda Rendle stepping down for health reasons, the ~5.1% dividend yield is doing most of the work in the return math.
Full thesis
Clorox is a textbook quality-staples turnaround that worked on margin and stalled on growth. Gross margin is back near record levels and the balance sheet is sound, but five years of flat revenue, a trailing-year free-cash-flow squeeze from the ERP transition, and an abrupt CEO transition cap the upside. The 5.1% yield from a near-Dividend-King franchise is the anchor; probability-weighted fair value lands around $105 — roughly 8% above the current price, with the dividend doing the heavy lifting on total return. The level that changes the calculus is closer to $90, where the yield approaches 5.5% and a sound franchise is being handed to you at a clear discount to its own history.
Clorox: A Margin Comeback in Search of a Growth Story
Gross margin clawed back from a 36% wartime trough to ~45%, EPS rebuilt from $1.21 to $6.56 — and almost none of it grew the top line. Now the CEO is leaving. What's a 113-year-old bleach franchise worth at a 5% yield?
The Bottom Line
The simplest version of the Clorox thesis: this is one of the most recognizable brand portfolios in the American home — bleach, Pine-Sol, Glad bags, Kingsford charcoal, Brita filters, Burt's Bees, Hidden Valley ranch — that got run over by input-cost inflation, a 2023 cyberattack, and a self-inflicted portfolio overhaul all at once, executed a genuinely impressive margin recovery to climb back out, and now trades at a clear discount to its own history because the one thing the recovery never delivered was growth. The market is pricing a no-growth staple with a fresh leadership question mark, and paying you a 5% yield to hold it.
The two variables that actually matter over the next 12-18 months are: (1) whether organic volume finally turns positive — proving the franchise can grow units, not just protect price and margin — and (2) whether the CEO transition lands a credible operator who keeps the ERP modernization and the "IGNITE / Streamlined Operating Model" on track. Everything else — the occasional plaintiff-bar "investigation," the energy-cost noise in any given quarter — is secondary to those two.
Where We've Been
CLX spent the past year giving back almost the entire post-recovery re-rate. The stock made a 52-week high around $132 in mid-2025 as the margin story peaked, then ground steadily lower all the way to an $84.70 low — a slide capped, not caused, by the late-May CEO announcement. At ~$97 it sits below both its 50-day (~$96) and 200-day (~$109) averages: a downtrend that's flattened but not yet turned.
CLX share price · Jun 2025 → Jun 2026 (approximate monthly)
The catalysts that moved it
| Date | Catalyst | Significance |
|---|---|---|
| Aug 2023 | Major cyberattack disrupts order processing and shipments | Knocked out a quarter of operations; FY2024 Q1 sales fell sharply — the scar still visible in the FY24 numbers |
| FY2024 | Portfolio overhaul: VMS/Better Health business sold; Argentina operations divested | Cleaned up the portfolio but reset the revenue base lower — a key reason reported sales look "flat" |
| FY2023–FY2025 | Gross margin recovery: 35.8% → 39.4% → 43.0% → 45.2% | The actual bull case made real — pricing, cost savings, and mix dragged margin back near record |
| Mid-2025 | Shares peak near $132 as the recovery narrative matures | The high-water mark; from here the question shifted from "can margin recover" to "where's the growth" |
| FY2026 | Enterprise-wide ERP / digital transformation goes live in phases | The largest systems overhaul in company history — efficiency prize on one side, execution and working-capital risk on the other |
| May 28, 2026 | CEO Linda Rendle to step down for health reasons; board opens CEO search | Removes a key operator mid-transformation; reintroduces succession risk into a slow-growth name |
A 113-Year-Old Brand Machine
Founded in Oakland in 1913 to make one product — liquid bleach — Clorox spent a century turning a commodity chemical into a trusted name and then stapling that trust to a portfolio of category leaders. The moat isn't technology. It's shelf space, brand recall, and the muscle memory of the American shopping cart.
Clorox began as the Electro-Alkaline Company, selling sodium hypochlorite bleach to Bay Area households. The genius of the next hundred years was recognizing that a brand consumers trust to disinfect their kitchen could be extended — and that the same retail relationships, manufacturing scale, and marketing engine could carry a much wider basket of everyday products. The result is a company where roughly four out of five brands hold the #1 or #2 share position in their category.
The portfolio sits in four segments: Health & Wellness (Clorox bleach, wipes, Pine-Sol, Liquid-Plumr, plus the CloroxPro and Clorox Healthcare professional lines); Household (Glad bags and wrap, Kingsford charcoal, Fresh Step and Scoop Away cat litter); Lifestyle (Hidden Valley dressings, Burt's Bees natural personal care, Brita water filtration); and International. These are not glamorous businesses. They are the kind of products people buy without thinking, replace on a schedule, and reach for by brand name — which is exactly what makes them durable.
Trust is the product. A shopper deciding between Clorox bleach and a private-label jug at half the price is making a judgment about whether "kills 99.9% of germs" is something to economize on. For disinfection, food storage, and water filtration — categories where the downside of the cheap option feels personal — brand trust commands a price premium that's remarkably sticky. That premium is the entire reason Clorox can run ~45% gross margins on what are, chemically, commodity inputs.
The COVID era was a double-edged gift. Demand for disinfecting products exploded in FY2020–FY2021 — revenue jumped to $6.7B then $7.3B and EPS hit $7.46 — but it pulled forward demand, over-built inventory expectations, and set up a brutal normalization. When the pandemic bump faded into a wall of input-cost inflation in FY2022, gross margin collapsed to 35.8% and EPS more than halved to $3.75. Then came the cyberattack and the portfolio surgery. By FY2023, EPS had cratered to $1.21. The five years since FY2020 have been, in effect, one long round-trip: a demand spike, a margin collapse, an operational crisis, and a methodical climb back.
How the Money Actually Works
Clorox sells high-frequency consumables at a premium, runs them through enormous retail scale, and converts the spread into cash it returns to shareholders. The recovery story lives almost entirely in the gross-margin line — and the tension in the model lives in the flat revenue line right above it.
The mechanism is simple: buy commodity inputs (resin, sodium hypochlorite, charcoal, agricultural goods), convert them into branded household staples, sell them to Walmart, Kroger, Costco, and the rest at a premium the brand supports, and collect the difference. Because these are low-priced, frequently-repurchased items, small moves in input costs or pricing swing the margin dramatically — which is exactly what happened on the way down in FY2022 and on the way back up since.
The clean read on the turnaround is the gross-margin chart below. Clorox pushed through multiple rounds of pricing, executed a cost-savings program, and let post-pandemic input costs deflate — dragging gross margin from a 35.8% low back to 45.2%, within reach of its pre-pandemic norm. That ~940 basis points is the single most important number in the recovery, and it's why EPS could round-trip from $1.21 back to $6.56 on essentially flat revenue.
But flat is the operative word. Net sales have hovered at roughly $7.1B every year since FY2020 — $7,341M, $7,107M, $7,389M, $7,093M, $7,104M. Some of that flatness is deliberate (the VMS and Argentina divestitures shrank the base; organic growth has run modestly positive underneath), but the takeaway holds: this is a company that has gotten more profitable without getting bigger. For a consumer-staples name, that's a perfectly respectable way to compound — until you need a re-rating, at which point the absence of a volume-growth story is exactly what caps the multiple.
Gross margin recovery · FY2022–FY2026E
Net revenue · FY2021–FY2026E
FY2025 at a glance
| Metric | FY2025 | Note |
|---|---|---|
| Net revenue | $7,104M | +0.2% YoY — flat |
| Gross margin | 45.2% | Up from 43.0% in FY24 |
| Operating income | $1,177M | 16.6% margin |
| Net income | $810M | EPS $6.56 (dil. $6.52) |
| Free cash flow | $761M | OCF $981M less $220M capex |
| Dividends paid | $602M | ~79% of FY25 FCF |
The cash-flow wrinkle worth watching
FY2025 free cash flow of $761M comfortably covered the ~$602M dividend. But the trailing-twelve-month picture has softened materially — operating cash flow has run closer to ~$575M and FCF nearer ~$380M as the ERP transition and working-capital swings bite. On that trailing basis, the dividend isn't fully covered by current-year cash generation.
This isn't a dividend-cut signal — the balance sheet, the ~76% EPS payout, and a near-50-year raise streak all argue for continuity. But it's the reason the payout cushion deserves attention rather than assumption: a near-Dividend-King is leaning on its balance sheet to bridge a transition year, and the new CEO inherits that math.
Why the Brand Holds the Shelf
The advantages stack: leading category share, the retail scale that earns prime shelf placement, a marketing engine that keeps brand recall high, and the simple fact that for a lot of these categories the cheap alternative feels like a risk consumers don't want to take.
Category leadership and shelf real estate
Roughly four of every five Clorox brands hold the #1 or #2 position in their category. That leadership is self-reinforcing at the shelf: retailers allocate the best placement to the brands that turn fastest, and the brands that get the best placement turn fastest. A challenger can't simply buy its way onto the eye-level shelf at Walmart — it has to earn velocity first, which is hard to do from a worse shelf position. The incumbency compounds.
Scale economics in commodity conversion
Clorox buys inputs and runs plants at a scale most competitors can't match, which matters enormously in categories where the product is a commodity and the cost structure is the game. That scale is what lets the company absorb input-cost spikes better than smaller rivals and is a big part of why the margin recovery was possible at all.
The trust premium — and where it's strongest
The moat is deepest exactly where the consequences of the cheap option feel personal: disinfection (Clorox, wipes, Healthcare), food contact (Glad), and water (Brita). In those categories the brand premium is remarkably durable. It's thinner in more discretionary or commoditized corners — charcoal, cat litter, dressings — where private label and challenger brands compete harder on price. The portfolio is a mix of fortress categories and contested ones, and the contested ones are where volume growth has been hardest to find.
The Sector, and Who's Pressing
Consumer staples is a low-growth, high-stability sector where the real contest is between branded incumbents and an increasingly capable private label — refereed by retailers who hold more power every year. Clorox competes against larger, more diversified peers on one flank and cheaper store brands on the other.
Bigger, broader peers above
Procter & Gamble, Kimberly-Clark, Colgate-Palmolive, and Church & Dwight are the branded competitive set. P&G in particular is a different weight class — vastly larger, more diversified, with a marketing and R&D budget Clorox can't match dollar-for-dollar. Clorox's defense isn't scale-versus-P&G; it's category focus. It doesn't need to beat P&G everywhere — it needs to remain the default in bleach, wipes, charcoal, and food storage, categories where it's the share leader and the giants are secondary.
Private label below — the structural pressure
The more persistent threat is from below. In a stretched-consumer environment, shoppers trade down, and store brands have gotten markedly better at narrowing the quality gap. Every round of branded price increases — exactly the lever Clorox pulled to rescue its margin — widens the price umbrella that private label sells under. The margin recovery and the volume stagnation are two sides of the same coin: Clorox protected price and profit, and the bill came due in units.
Retailer power — the referee with leverage
Walmart, Costco, Amazon, and Kroger control access to the consumer, and they use it. Concentrated retail buyers push back hard on price increases, promote their own private-label lines, and dictate shelf and promotional terms. For a supplier whose entire model depends on premium pricing surviving the retailer negotiation, that pressure is permanent and only grows as retail concentrates further.
What would actually change the growth picture
The honest answer is innovation and mix — premium line extensions (the Healthcare professional disinfecting launches, Burt's Bees, protein-forward Hidden Valley adjacencies) that command higher price points and pull the blended growth rate up. None of these is individually a needle-mover, but collectively they're the difference between a flat-revenue dividend stock and a low-single-digit grower that earns a higher multiple. That's the bar.
The Cyberattack, the ERP, and the Operating-Model Overhaul
Three threads of the same multi-year reset: a 2023 cyberattack that exposed how fragile the old systems were, a top-to-bottom ERP and digital modernization that is the most ambitious systems project in the company's history, and a "Streamlined Operating Model" meant to take cost out permanently. Done right, it's a structurally more efficient Clorox. Done badly, it's exactly the kind of self-inflicted disruption that breaks a turnaround.
Replace the plumbing. The August 2023 cyberattack didn't just cost a quarter of sales — it laid bare how much of Clorox ran on aging, fragmented systems. The response is a multi-year migration to a unified, cloud-based ERP and a redesigned digital backbone, paired with a Streamlined Operating Model that flattens the organization and embeds cost discipline. The prize is structural: faster decision-making, lower overhead, better supply-chain visibility, and a platform that can actually support the innovation-led growth the company needs.
The catch is the transition itself. Large ERP cutovers are notorious for short-term disruption — inventory timing, order-to-cash friction, working-capital swings. That's almost certainly part of why trailing free cash flow has compressed even as the income statement looks healthy. The market has seen enough botched ERP transitions to discount the risk, and a stretch of plaintiff-bar "investigations" in mid-2026 is the predictable noise that attaches to any company managing a complex disclosure path through a transformation. None of those investigations is, on its own, a thesis-changer — but they're a reminder the transition is being watched closely.
The strategic logic is sound. A consumer-staples company that can't grow units has exactly two levers left: price (which it has already pulled hard, at the cost of volume) and cost (which is what the operating-model overhaul is for). Taking structural cost out is the most reliable way for a no-growth franchise to keep compounding EPS — and if the ERP platform also enables faster innovation, it addresses the volume problem too. The transformation is, in effect, Clorox's answer to both halves of its central tension.
The reason it now carries more risk than it did a month ago is leadership. Rendle was the operator steering this. Handing a complex, multi-year systems-and-org transformation to a new CEO mid-flight is the single biggest reason to want a better entry price than $97. A capable successor who keeps the program on rails turns this section into the bull case; a disruptive transition turns it into the bear case.
SWOT
Where Clorox wins structurally, where the thesis leaks, where the upside hides, and what would actually break it.
Strengths
- Category leadership: ~80% of brands hold #1 or #2 share — the kind of incumbency that earns prime shelf and durable pricing power
- Margin recovery executed: Gross margin rebuilt from 35.8% to 45.2%, dragging EPS from $1.21 back to $6.56 on flat revenue
- Trust-premium brands: Strongest exactly where the cheap option feels risky — disinfection, food contact, water filtration
- Income credentials: ~5.1% yield, a near-50-year raise streak (closing on Dividend King status), and a low 0.55 beta — a genuine defensive holding
- Sound balance sheet: Net debt/EBITDA ~2.5x with high returns on capital (ROIC ~17%, ROE ~28%)
Weaknesses
- No top-line growth: Revenue stuck at ~$7.1B for five straight years — the recovery never produced a volume-growth story
- Trailing FCF compression: TTM free cash flow (~$380M) running below the ~$602M dividend as the ERP transition bites
- Pricing-led recovery has a cost: The price increases that saved margin widened the umbrella for private label and pressured units
- Commodity input exposure: Resin, energy, and agricultural costs swing margins sharply in both directions — the recovery is partly cyclical, not all structural
Opportunities
- Operating-model cost-out: Structural cost reduction is the cleanest path to compounding EPS without needing volume growth
- ERP-enabled efficiency: A modern digital backbone can lift supply-chain visibility, working-capital efficiency, and speed to market
- Premium innovation and mix: Healthcare professional lines, Burt's Bees, and adjacencies that pull the blended growth rate up
- Multiple re-rating: At ~15x trailing vs. a ~22-25x history, even a modest growth signal could re-rate the stock meaningfully
- Dividend King milestone: Crossing 50 consecutive annual increases broadens the income-investor and index ownership base
Threats
- CEO succession risk: Losing the operator steering the transformation mid-flight — the freshest and least-priced risk in the name
- Private-label trade-down: A stretched consumer and better store brands erode the volume base and cap pricing power
- ERP transition disruption: A botched cutover would hit inventory, order-to-cash, and cash flow — a self-inflicted setback at a vulnerable moment
- Input-cost re-inflation: A renewed spike in resin, energy, or ag costs would compress the hard-won margin gains
- Retailer leverage: Concentrating retail buyers pushing back on price and promoting private label is a permanent, intensifying headwind
Bull · Base · Bear
Twelve-month forward scenarios off a ~$97 starting price, before dividends. Add roughly 5 points of yield to each for total return. Probabilities reflect a sound franchise carrying a fresh leadership question — the distribution is tighter and lower-variance than a growth name, as a 0.55-beta staple should be.
$125
What has to go right: The board names a credible operator who keeps the ERP transformation and cost-out on track. Organic volume turns positive, proving the franchise can grow units, not just price. Gross margin holds at 45%+ and EPS pushes toward $7.40. The market re-rates from ~15x back toward 17-18x as a growth signal returns.
$108
The most likely path: Revenue stays roughly flat to up low-single-digits, EPS lands near $7, and margins hold. The CEO transition is orderly but uneventful. The stock drifts back toward the analyst consensus zone (~$105) on the strength of the yield and steady execution rather than any re-rating. A dividend-compounder grind.
$78
What breaks it: The leadership transition disrupts execution; the ERP cutover stumbles and hits cash flow. Input costs re-inflate and squeeze the recovered margin. Private-label trade-down keeps eroding volume, FCF stays below the dividend, and the payout-growth streak pauses. The multiple de-rates toward ~11x.
Price scenarios · Jun 2026 → Jun 2027 (before dividends)
Time-Horizon Outlook
The near-term is about the CEO search and whether the stock has found a floor. The medium-term is about whether volume finally turns. The long-term is about whether the modernized, cost-leaner Clorox can grow at all — or whether it's a permanent flat-revenue income vehicle.
Jun-Sep 2026
The CEO search dominates. The market wants to see a credible operator named — ideally an internal continuity candidate or a proven staples executive — to de-risk the transformation. Until then, expect the stock to trade around the $90-100 range it's settled into.
- Who gets named CEO, and whether they signal continuity on the transformation
- Whether the $84.70 low holds as a floor on any broad-market weakness
- Risk: a protracted or surprising search keeps the overhang in place
Sep-Dec 2026
The first couple of quarters under the new leadership — and the window where organic volume either inflects positive or confirms the flat-growth read. Watch the cash-flow line for evidence the ERP transition drag is fading.
- Organic volume trend — the single number that decides growth vs. no-growth
- Free cash flow recovering back toward dividend coverage
- Risk: another quarter of price-led, volume-negative growth confirms the cap on the multiple
The proof year
If the thesis works: the ERP transition is complete and delivering efficiency, cost-out is showing in the margin, innovation is nudging the growth rate up, and the new CEO has a clean quarter or two of execution behind them. That's the setup for a re-rating off ~15x.
- Operating-model savings visible in the margin and cash flow
- Dividend King status reached, broadening the ownership base
- Risk: the transformation finishes but the growth still isn't there
The long question
The defining long-run question: is Clorox a low-single-digit grower that deserves a low-20s multiple, or a permanently flat-revenue income vehicle that deserves a low-teens one? The answer determines whether this is a compounder or a bond-proxy — and the gap between those outcomes is most of the upside.
- Whether innovation and mix sustainably lift organic growth above ~2%
- Whether the trust premium holds against a structurally better private label
- Tail risk: a secular shift in how consumers value brand in commoditized staples
Risk Matrix
Ranked by what would actually move the stock 15%+ in either direction.
The Bottom Line, Revisited
Strip away the noise and what's left is a high-quality, low-beta brand franchise that fixed its margin, can't yet prove it can grow, and just lost the operator who was steering the fix — trading at a discount to its history and paying you 5% to be patient.
Clorox did the hard, unglamorous work of a real turnaround: it took a gross margin that had collapsed to 35.8% and rebuilt it to 45.2%, dragging earnings from a $1.21 nadir back to $6.56, all while absorbing a cyberattack and reshaping its portfolio. That's a genuinely impressive operating recovery, and the balance sheet, the returns on capital, and the dividend pedigree are all real strengths.
But the recovery answered the margin question and left the growth question wide open — revenue has been flat for five years, the pricing that saved the margin pressured volume, and the cash-flow line is leaning on the balance sheet through a transition year. Now the CEO is leaving mid-transformation. None of that makes Clorox a broken business; it makes it a fully-valued one for what it is — a flat-revenue income compounder priced at a discount to its history precisely because the market isn't sure the growth is coming.
The probability-weighted fair value lands around $105 — modest price upside, with the ~5.1% yield doing most of the total-return work. That's a perfectly reasonable thing to own for income from a defensive franchise. But the symmetric risk/reward and the open CEO seat argue for patience on the entry: $90 is where the yield approaches 5.5% and you're clearly being paid to take on a transition that, in all likelihood, resolves fine.